Healthcare, Pharma & Life Sciences

Mayo Clinic Jacksonville Taps Rainfall AI for CMS TEAM Compliance

Image
Mayo Clinic Jacksonville Taps Rainfall AI for CMS TEAM Compliance

San Francisco – September 08, 2026 -- Rainfall Health announced that Mayo Clinic in Jacksonville, Florida will deploy its AI-driven platform to manage care coordination and compliance under the Centers for Medicare & Medicaid Services' Transforming Episode Accountability Model (TEAM), a mandatory payment program that took effect September 08, 2026.

CMS mandates 721 hospitals into value-based surgical episode program

CMS selected 721 hospitals for the first TEAM cohort, requiring value-based reimbursement across five high-volume surgical episodes. Hospitals missing cost and quality benchmarks face financial penalties, while those that meet targets can access reconciliation bonuses worth up to $85 million in new revenue.

Bayesian Health Wins First Medicare Payment for Sepsis AI

Image
Bayesian Health Wins First Medicare Payment for Sepsis AI

New York – September 08, 2026 -- Bayesian Health has secured a New Technology Add-on Payment (NTAP) from the Centers for Medicare and Medicaid Services, making it the first continuous sepsis monitoring technology to hold both FDA clearance and a dedicated Medicare reimbursement pathway.

The approval, issued under CMS's FY 2027 Inpatient Prospective Payment System Final Rule, takes effect September 08, 2026, and allows hospitals using Bayesian's FDA-cleared sepsis flagging device to bill Medicare an add-on payment of up to $61.84 per eligible inpatient case.

Alteogen Signs Up to $3.2B Novartis Deal for Hybrozyme SC Platform

Daejeon – – September 08, 2026 -- Alteogen Inc. (KOSDAQ: 196170) has signed an option and license agreement with Novartis worth up to US$3,223 million, granting the Swiss drugmaker rights to develop subcutaneous formulations for multiple Novartis products using Alteogen's ALT-B4 hyaluronidase.

Novartis secures multi-product option rights to ALT-B4 technology

Under the agreement, Novartis will hold multiple options to obtain exclusive rights to develop and commercialize subcutaneous formulations for several of its products using ALT-B4 (berahyaluronidase alfa). The enzyme, built on Alteogen's proprietary Hybrozyme platform, converts biologics normally delivered via intravenous infusion into faster, more convenient subcutaneous injections by temporarily depolymerizing hyaluronan in the extracellular matrix.

RZL-012 Hits All Phase 3 Endpoints, Clears Path to China NDA Filing

Hod Hasharon, Israel & Shanghai – September 08, 2026 -- Raziel Therapeutics and Fosun Pharma reported that RZL-012, an injectable lipolytic drug for submental fat reduction, met every primary and secondary endpoint in a 480-patient Phase 3 trial in China, with the primary responder rate outperforming placebo by 30 percentage points after a single treatment cycle.

Pivotal China trial clears statistical bar with wide margin over placebo

The registration study, conducted with Fosun Pharma affiliate JuveStar, enrolled 360 patients on active treatment and 120 on placebo, evaluating efficacy 84 days after one treatment cycle. Results showed a decisive statistical advantage across all measured endpoints, according to the companies.

TCAI Becomes First US Site to Trial New Pulsed Field Ablation System

Austin, Texas – September 08, 2026 -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has become the first center in the United States to enroll a patient in a clinical trial evaluating a next-generation pulsed field ablation mapping and ablation system for paroxysmal and persistent atrial fibrillation.

TCAI performs first US procedure under global trial protocol

Andrea Natale, M.D., executive medical director of TCAI and global principal investigator for the trial, performed the inaugural procedure. The study is designed to assess the safety and efficacy of the catheter-based system in patients with paroxysmal atrial fibrillation, defined as symptomatic episodes lasting seven days or less, and persistent atrial fibrillation, sustained arrhythmia lasting longer than one week.

NovaGo Raises $30M Series B to Advance Spinal Injury Drug Trial

Image
NovaGo Raises $30M Series B to Advance Spinal Injury Drug Trial

Schlieren – September 08, 2026 -- NovaGo Therapeutics AG has closed a Series B financing round of CHF 24 million ($30 million), led by Neurimmune and Pureos, to fund a proof-of-concept trial for its anti-Nogo-A antibody in acute spinal cord injury.

The equity round drew participation from existing and new investors and was supplemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.

NovaGo to enroll 120 patients across Germany, Spain and Switzerland

Proceeds will push the company's lead program, NG004, into a fully randomized, double-blind proof-of-concept study recruiting 120 acute spinal cord injury patients at centers in the three countries. NG004 is a fully human antibody designed to block Nogo-A, a protein that inhibits nerve fiber regeneration and neuroplasticity in the central nervous system.

Haier Biomedical Debuts Automated -80°C Storage at ISPE Singapore 2026

Image
Haier Biomedical Debuts Automated -80°C Storage at ISPE Singapore 2026

Singapore – September 08, 2026 -- Haier Biomedical (SHA: 688139) reported that revenue from pharmaceutical clients rose 23% year-on-year in the first half of 2026, while laboratory solutions revenue grew 19%, as the company unveiled new automated bio-storage and connected pharmaceutical technologies at the ISPE Singapore Conference & Exhibition 2026.

Automated -80°C storage system makes international exhibition debut

Held August 20-21 at Suntec Singapore, the event served as the venue for the first international showing of Haier Biomedical's automated ultra-low-temperature storage solution. The system combines automated -80°C storage with intelligent sample management to improve workflow efficiency and traceability for pharmaceutical companies and research organizations handling high-value samples.

Medtronic to Invest $700M in Cornerstone Robotics for Sentire Rights

Hong Kong – September 08, 2026 -- Medtronic (NYSE: MDT) will invest approximately $700 million in Hong Kong-based Cornerstone Robotics as part of a strategic alliance granting the U.S. medtech giant distribution rights to the Sentire surgical robotic system in select markets outside the United States where the device is approved.

Medtronic gains distribution rights to Sentire outside the U.S.

The agreement covers markets where Sentire has already secured regulatory clearance, positioning the system alongside Medtronic's existing Hugo robotic surgical platform. Sentire received approval from China's National Medical Products Administration in 2024, followed by CE marking in the European Union and clearance from Singapore's Health Sciences Authority in May 2026 for general, gynecological, thoracic and urological minimally invasive procedures.

Medtronic Invests $700M in Cornerstone Robotics for Sentire Rights

Hong Kong – September 08, 2026 -- Medtronic (NYSE: MDT) will make a strategic investment of approximately $700 million in Hong Kong-based Cornerstone Robotics, securing distribution rights for the Sentire surgical system in select markets outside the United States where the device is already cleared.

Medtronic secures rights to Sentire outside the US market

The agreement gives Medtronic distribution rights to Cornerstone Robotics' Sentire surgical system in ex-US markets where regulatory approval has already been granted. Matt Anderson, Senior Vice President and President of Medtronic's surgical solutions division, said the deal expands robotics choice for patients and positions Sentire as a complement to Medtronic's existing Hugo platform.

HRC Fertility Names Dr. Robert Boostanfar Chief Medical Officer

Image
HRC Fertility Names Dr. Robert Boostanfar Chief Medical Officer

Los Angeles – September 08, 2026 -- HRC Fertility, a fertility network operating 15 locations across California and Las Vegas, has appointed longtime physician Robert Boostanfar, M.D., as its first Chief Medical Officer, giving the organization a senior clinical leader as it scales operations across its 34-physician network.

Dr. Boostanfar gains oversight of clinical quality across HRC's full network

In the newly created role, Dr. Boostanfar will oversee physician engagement, clinical quality initiatives, innovation and medical performance across HRC Fertility's network of 34 physicians. He will coordinate with physicians, laboratories and clinical teams to standardize care protocols across the organization's 15 sites in the California Bay Area, Los Angeles, Orange County, San Diego County and Las Vegas.